A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Summary

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A*02 expression.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumor, Adult
• Colorectal Cancer
• Non-Small Cell Lung
• NSCLC (Non-small Cell Lung Cancer)
• Cancer
• Colon Cancer
• Rectal Cancer
• Lung Cancer
• CRC
• Head and Neck Squamous Cell Cancer
• HNSCC
• Renal Cell Carcinoma
• RCC
• Kidney Cancer
• Triple Negative Breast Cancer
• TNBC
• Colorectal Adenocarcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

A2 Biotherapeutics Inc.

Last updated on ClinicalTrials.gov

September 9, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites